Background: In many countries, hypertension in the pediatric population is considered a
serious risk of mortality and morbidity. In this respect, it is central to design and develop new …

Enalapril is an off-patent angiotensin-converting enzyme inhibitor for which no paediatric
age-appropriate formulation is commercially available in Europe, and enalapril maleate …

The development of orodispersible mini-tablets (ODMTs) for paediatric use has gained
importance within recent years as European authorities set up regulations for developing …

Introduction Comparative pharmacokinetic (PK) data analysis of drugs administered using
developed child-appropriate and market authorized dosage formulation is sparse and is …

The angiotensin‐converting enzyme inhibitor enalapril is commonly used to treat chronic
heart failure in children. Because some children are unable to swallow capsules or tablets, a …

The new European regulations on paediatric medicines and recent WHO recommendations
have induced an increased need for research into novel child-appropriate dosage forms …

Fast disintegrating tablets (FDTs) dissolve or disintegrate in the mouth without the need of
additional water. The aim of the present study was to formulate FDTs of Valsartan for the …

In the present work, oral dispersible tablets of Enalapril maleate were prepared using three
different superdisintegrants and a co-processed superdisintegrant consisting of …

Introduction: To provide the patient with the most convenient mode of administration, there is
a need to develop fast-disintegrating tablets, which disintegrate and dissolve rapidly in the …

The objective of the present study was to prepare the fast disintegrating tablet of Salbutamol
Sulphate, Cetirizine Hydrochloride in combined tablet dosage form for respiratory disorders …